phone icon  Int'l : +1-503-894-6022
Allied Market Research
0
Shopping Cart is Empty..
$ 0

Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option for treating various cancer types, especially for blood cancer (leukemia). Rising incidence of various cancer conditions, growing popularity of advance therapies (biological and targeted drug therapies), patents expiration of leading drugs along with commercialization of follow-on-biologics are the few factors driving the growth of global cancer/oncology drugs market. However, high cost involved in new Oncology drug development pipeline and chemotherapy drugs coupled with threat of failure and adverse effects associated with cancer treatment drugs therapies may restrain the development of the oncology market. Market dynamics including commercialization of advanced therapeutics such as targeted and immunotherapies would reduce the negative influence of restraints and fuel the growth of oncology pharmaceutical companies and cancer drugs market. Market by therapeutic modalities including Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy) and Hormonal Therapy is driving the cancer drugs industry worldwide. In addition, cancer types such as Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Prostate Cancer, Respiratory/Lung Cancer, Skin Cancer and other Cancers will drive in huge investments for drug discovery.

The global oncology drugs market is expected to reach at $111.9 billion by 2020 registering a CAGR of 7.1% from 2014 to 2020. Patent expiration of key oncology medicines such as Herceptin, Erbitux, Rituxan and Avastin, is expected to boost the growth of cancer biosimilars market by 2020. Going further, the biological therapies are expected to dominate the cancer market by 2020, due to their high efficacy, target specific action and less toxicity. Blood cancer drugs market was the largest revenue generating segment in 2013 owing to the high cost of drugs (immunotherapies) used for the cancer treatment such as blood cancer. Furthermore, cancer research particularly for Melanoma would open avenues.

Geographically, North America, dominates the market followed by Europe. North America accounted for about ~38% share in the overall oncology drugs market in 2013 owing to the heavy investments by multinational companies in research and development of cancer drugs, particularly immune therapeutics, favorable reimbursement policies, and high adoption rate of immunotherapies. On the other hand, Asia-Pacific market would grow at the promising CAGR of 8.7% during the forecast period. Such high growth rate is majorly due to increasing awareness towards advanced therapies namely immunotherapies and increase in per capita healthcare spending.

Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co. and GlaxoSmithKline. Companies operating in the Oncology drugs market focus on several strategies such as collaboration, approval and acquisition.

Global-Oncology_Cancer-Drugs-Market-Sidebar

ONCOLOGY DRUGS MARKETKEY BENEFITS

  • The report provides the quantitative analysis of the current trends, size and estimations for the forecast period 2013-2020 that assists in identifying the prevailing opportunities to capitalize on
  • The report helps in understanding the strategies adopted by various companies for consolidating their positions in the industry.
  • The report provides comprehensive analysis of factors that drive and restrict the growth of the cancer drugs market
  • Demand and supply conditions of cancer drugs across all geographic regions are comprehensively analyzed
  • Competitive intelligence (of leading manufacturers) helps in understanding the competitive market scenario and opportunities across the geographies
  • SWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companies

ONCOLOGY/CANCER DRUGS MARKET SEGMENTATION

The Oncology drugs market is segmented by the therapeutic modalities, cancer types and geography.

BY THERAPEUTIC MODALITIES

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy (Biologic Therapy)
  • Hormonal Therapy
  • Others

BY CANCER TYPES

  • Blood Cancer
  • Breast Cancer
  • Gastrointestinal Cancer
  • Prostate Cancer
  • Respiratory/Lung Cancer
  • Skin Cancer
  • Other Cancers

BY GEOGRAPHY

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Others
  • Asia-Pacific
    • India
    • China
    • Japan
    • Australia
    • Others
  • LAMEA
    • GCC (Gulf Corporation Council)
    • Others
* Pricing on the website is provided for single users licenses only. All reports will be provided in a PDF format for download. To purchase multi-user licenses, please contact us at +1-800-792-5285 or send an email to sales@alliedmarketresearch.com
Title/ Chapter Name

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1 Market beyond what to expect by 2025

2.1.1 Moderate growth scenario
2.1.2 Rapid growth scenario
2.1.3 Diminishing growth scenario

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings

3.3.1 Top Factors impacting oncology drugs market
3.3.2 Top investment pockets of oncology drugs market
3.3.3 Top winning strategies of oncology drugs market

3.4 Porters five forces analysis

3.4.1 Bargaining power of buyers (low)
3.4.2 Bargaining power of suppliers (moderate)
3.4.3 Threat of new entrants (Low)
3.4.4 Threat of substitutes (moderate)
3.4.5 Intense competitive rivalry

3.5 Value chain analysis

3.5.1 Primary activities
3.5.2 Support activities

3.6 Government regulations and reimbursement

3.6.1 Regulations in United States
3.6.2 Regulations in Europe
3.6.3 Regulations in Asia-Pacific
3.6.4 Reimbursement scenario

3.7 Patent analysis

3.7.1 Patent Analysis by type of patents
3.7.2 Patent analysis by geography

3.8 Market share analysis, 2013
3.9 Clinical trials for oncology drugs
3.10 Market dynamics

3.10.1 Drivers

3.10.1.1 Rising incidence and prevalence of various cancer types
3.10.1.2 Growing importance of biological and targeted drug therapies
3.10.1.3 Expiration of key patents and biosimilars impact
3.10.1.4 Acquisitions and collaborations bolt-on strategies driving the market growth

3.10.2 Restraints

3.10.2.1 High cost of drug development and threat of failure
3.10.2.2 Adverse effects of anti-cancer drug therapy

3.10.3 Opportunities

3.10.3.1 Advancement of anti-cancer drugs research
3.10.3.2 Personalized medicine approach

Chapter: 4 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES

4.1 Chemotherapy

4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast

4.2 Targeted therapy

4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast

4.3 Immunotherapy (biologics therapy)

4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast

4.4 Hormonal therapy

4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast

4.5 Others

4.5.1 Market size and forecast

Chapter: 5 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY CANCER TYPES

5.1 Blood cancer

5.1.1 Epidemiology prevalence and incidence
5.1.2 Trends in blood cancer treatment
5.1.3 Market size and forecast

5.2 Breast cancer

5.2.1 Epidemiology prevalence and incidence
5.2.2 Trends in breast cancer treatment
5.2.3 Market size and forecast

5.3 Gastrointestinal cancer

5.3.1 Epidemiology prevalence and incidence
5.3.2 Trends in treatment of gastrointestinal cancer
5.3.3 Market size and forecast

5.4 Prostate cancer

5.4.1 Epidemiology prevalence and incidence
5.4.2 Trends in treatment of prostate cancer
5.4.3 Market size and forecast

5.5 Respiratory/lung cancer

5.5.1 Epidemiology prevalence and incidence
5.5.2 Trends in treatment of lung Cancer
5.5.3 Market size and forecast

5.6 Skin cancer

5.6.1 Epidemiology prevalence and incidence
5.6.2 Trends in treatment of skin cancer
5.6.3 Market size and forecast

5.7 Other cancers

5.7.1 Trends in treatment of other cancer types

Chapter: 6 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY

6.1 North America

6.1.1 Market size and forecast
6.1.2 United States

6.1.2.1 Key market trends
6.1.2.2 Market size and forecast

6.1.3 Canada

6.1.3.1 Key market trends
6.1.3.2 Market size and forecast

6.1.4 Mexico

6.1.4.1 Market size and forecast

6.2 Europe

6.2.1 Key market trends
6.2.2 Market size and forecast
6.2.3 Germany

6.2.3.1 Key market trends
6.2.3.2 Market size and forecast

6.2.4 France

6.2.4.1 Key market trends
6.2.4.2 Market size and forecast

6.2.5 United Kingdom

6.2.5.1 Key market trends
6.2.5.2 Market size and forecast

6.2.6 Others

6.2.6.1 Key market trends
6.2.6.2 Market size and forecast

6.3 Asia Pacific

6.3.1 Key market trends

6.3.1.1 Market size and forecast

6.3.2 India

6.3.2.1 Key market trends
6.3.2.2 Market size and forecast

6.3.3 China

6.3.3.1 Key market trends
6.3.3.2 Market size and forecast

6.3.4 Japan

6.3.4.1 Key market trends
6.3.4.2 Market size and forecast

6.3.5 Australia

6.3.5.1 Key market trends
6.3.5.2 Market size and forecast

6.3.6 Others

6.4 LAMEA

6.4.1 GCC (gulf corporation council)

6.4.1.1 Key Market Trends
6.4.1.2 Market size and forecast

6.4.2 Others

6.4.2.1 Market size and forecast

Chapter: 7 COMPANY PROFILES

7.1 Amgen Inc.

7.1.1 Company overview
7.1.2 Amgen Inc. snapshot
7.1.3 Financial performance
7.1.4 Operating business segment overview
7.1.5 Key strategies and development
7.1.6 SWOT analysis

7.2 Johnson and Johnson

7.2.1 Company overview
7.2.2 Johnson & Johnson snapshot
7.2.3 Operating business segment overview
7.2.4 Financial performance
7.2.5 Key strategies moves and development
7.2.6 SWOT Analysis

7.3 Roche Diagnostics

7.3.1 Company overview
7.3.2 Roche Diagnostics snapshot
7.3.3 Operating business segment overview
7.3.4 Financial performance
7.3.5 Key strategies moves and development
7.3.6 SWOT analysis

7.4 GlaxoSmithKline PLC

7.4.1 Company overview
7.4.2 GlaxoSmithKline PLC Snapshot
7.4.3 Operating business segment overview
7.4.4 Financial performance
7.4.5 Key strategies move and development
7.4.6 SWOT Analysis of GlaxoSmithKline PLC

7.5 Merck & Company

7.5.1 Company overview
7.5.2 Merck & Company snapshot
7.5.3 Operating business segment overview
7.5.4 Financial performance
7.5.5 Key strategies move and development
7.5.6 SWOT analysis

7.6 Novartis AG

7.6.1 Company overview
7.6.2 Novartis AG snapshot
7.6.3 Operating business segment overview
7.6.4 Financial performance
7.6.5 Key strategies move and development
7.6.6 SWOT analysis

7.7 Pfizer

7.7.1 Company overview
7.7.2 Pfizer snapshot
7.7.3 Operating business segment overview
7.7.4 Financial performance
7.7.5 Key strategies move and development
7.7.6 SWOT analysis

7.8 Sanofi

7.8.1 Company overview
7.8.2 Sanofi snapshots
7.8.3 Operating business segment overview
7.8.4 Financial performance
7.8.5 Key strategies move and development
7.8.6 SWOT analysis

7.9 Eli Lilly and Company

7.9.1 Company overview
7.9.2 Eli Lilly and company snapshots
7.9.3 Operating business segment overview
7.9.4 Financial performance
7.9.5 Key strategies move and development
7.9.6 SWOT analysis

7.10 Celgene Corporation

7.10.1 Company overview
7.10.2 Celgene corporation snapshots
7.10.3 Operating business segment overview
7.10.4 Financial performance
7.10.5 Key strategies move and development
7.10.6 SWOT analysis

LIST OF TABLES

TABLE 1 MODERATE GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 2 RAPID GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 3 DIMINISHING GROWTH SCENARIO OF ONCOLOGY/ CANCER DRUGS MARKET BY GEOGRAPHY, 2020 2025, ($MILLION)
TABLE 4 APPLICABLE STANDARDS FOR THE UNITED STATES ANTICANCER DRUG DEVELOPMENT PROCESS
TABLE 5 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSES
TABLE 6 CLINICAL LABORATORY FEE SCHEDULE (CLFS) REIMBURSEMENT CODES
TABLE 7 CLINICAL TRIALS FOR ONCOLOGY DRUGS
TABLE 8 WORLDWIDE ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (EXCLUDING NON-MELANOMA SKIN CANCER) (2012)
TABLE 9 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)
TABLE 10 LIST OF KEY PRODUCTS WITH THEIR PATENT EXPIRY DATES
TABLE 11 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF ANTI-CANCER DRUGS
TABLE 12 GLOBAL ONCOLOGYDRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 13 GLOBAL CHEMOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 14 GLOBAL TARGETED THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 15 CANCER IMMUNOTHERAPEUTICS AND THEIR CUMULATIVE PRICES
TABLE 16 GLOBAL IMMUNOTHERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 17 GLOBAL HORMONAL THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 18 GLOBAL OTHER THERAPY DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 19 GLOBAL ONCOLOGYDRUGS MARKET BY CANCER TYPES, 2013 2020 ($MILLION)
TABLE 20 INCIDENCE AND PREVALENCE OF BLOOD CANCER TYPES IN UNITED STATES
TABLE 21 USFDA APPROVED DRUGS FOR THE TREATMENT OF BLOOD CANCERS
TABLE 22 GLOBAL BLOOD CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 23 WORLDWIDE INCIDENCE AND PREVALENCE OF BREAST CANCER (2012)
TABLE 24 GLOBAL BREAST CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 25 WORLDWIDE INCIDENCE AND PREVALENCE OF GASTROINTESTINAL CANCER (2012)
TABLE 26 GLOBAL GASTROINTESTINAL CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 27 WORLDWIDE INCIDENCE AND PREVALENCE OF PROSTATE CANCER (2012)
TABLE 28 DRUGS USED IN PROSTATE CANCER AND THEIR REVENUE (2013)
TABLE 29 GLOBAL PROSTATE CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 30 WORLDWIDE INCIDENCE AND PREVALENCE OF LUNG CANCER (2012)
TABLE 31 LIST OF NEW THERAPEUTIC AGENTS FOR LUNG CANCER TREATMENT
TABLE 32 GLOBAL RESPIRATORY/LUNG CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 33 GLOBAL SKIN CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 34 WORLDWIDE INCIDENCE AND PREVALENCE OF CERVICAL CANCER (2012)
TABLE 35 GLOBAL OTHER CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 36 GLOBAL ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 37 NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET BY GEOGRAPHY, 2013 2020 ($MILLION)
TABLE 38 COSTS PER THERAPY OF THE COMMON CANCER DRUGS IN THE UNITED STATES:
TABLE 39 UNITED STATES ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 40 CANADA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 41 MEXICO ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 42 NEW ANTICANCER DRUGS APPROVED BY E MA 2013
TABLE 43 EUROPE ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 44 GERMANY ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 45 FRANCE ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 46 UNITED KINGDOM ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 47 OTHERS ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 48 ASIA PACIFIC ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 49 INDIA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 50 CHINA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 51 JAPAN ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 52 AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 53 OTHERS ONCOLOGY/CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 54 LAMEA ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 55 GCC ONCOLOGY/CANCER DRUGS MARKET BY COUNTRIES, 2013 2020 ($MILLION)
TABLE 56 LATIN AMERICAN/ AFRICAN COUNTRIES AND THEIR PRICING POLICIES FOR CANCER THERAPIES
TABLE 57 OTHERS
CANCER/ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITIES, 2013 2020 ($MILLION)
TABLE 58 AMGEN INC. SNAPSHOT
TABLE 59 JOHNSON & JOHNSON SNAPSHOT
TABLE 60 JOHNSON AND JOHNSON OPERATING SEGEMENTS
TABLE 61 ROCHE DIAGNOSTICS SNAPSHOT
TABLE 62 ROCHE DIAGNOSTICS OPERATING SEGEMENTS
TABLE 63 GLAXOSMITHKLINE PLC SNAPSHOT
TABLE 64 GLAXOSMITHKLINE PLC OPERATING SEGEMENTS
TABLE 65 MERCK & COMPANY SNAPSHOT
TABLE 66 MERCK & CO. OPERATING SEGEMENTS
TABLE 67 NOVARTIS AG SNAPSHOT
TABLE 68 NOVARTIS AG OPERATING SEGEMENTS
TABLE 69 PFIZER SNAPSHOT
TABLE 70 PFIZER OPERATING SEGEMENTS
TABLE 71 SANOFI SNAPSHOTS
TABLE 72 SANOFI OPERATING SEGEMENTS
TABLE 73 ELI LILLY AND COMPANY SNAPSHOTS
TABLE 74 ELI LILLY AND COMPANY OPERATING SEGEMENTS
TABLE 75 CELGENE CORPORATION SNAPSHOTS

LIST OF FIGURES

FIG. 1 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN MODERATE GROWTH SCENARIO
FIG. 2 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN RAPID GROWTH SCENARIO
FIG. 3 IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET IN DIMINISHING GROWTH SCENARIO
FIG. 4 TOP FACTORS IMPACTING ONCOLOGY DRUGS MARKET (2014-2020)
FIG. 5 TOP INVESTMENT POCKETS OF ONCOLOGY DRUGS MARKET (2013)
FIG. 6 TOP WINNING STRATEGIES FOR GLOBAL ONCOLOGY DRUG MARKET (2011-2013)
FIG. 7 TOP WINNING STRATEGIRS BY SUBTYPE
FIG. 8 PORTERS FIVE FORCES ANALYSIS OF ONCOLOGY DRUGS MARKET
FIG. 9 VALUE CHAIN ANALYSIS OF GLOBAL CANCER DRUGS MARKET
FIG. 10 PATENT ANALYSIS BY TYPE OF PATENTS (2011-2015)
FIG. 11 PATENT ANALYSIS BY GEOGRAPHY (2011-2015)
FIG. 12 MARKET SHARE ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET (2013)
FIG. 13 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 14 AMGEN INC. REVENUE BY GEOGRAPHY (2013)
FIG. 15 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2013)
FIG. 16 SWOT ANALYSIS OF AMGEN INC.
FIG. 17 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY GEOGRAPHY (2013)
FIG. 18 FINANCIAL REVENUE OF JOHNSON & JOHNSON BY BUSINESS UNITS (2013)
FIG. 19 SWOT ANALYSIS OF JOHNSON & JOHNSON
FIG. 20 FINANCIAL REVENUE OF ROCHE DIAGNOSTICS BY GEOGRAPHY (2013)
FIG. 21 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2013)
FIG. 22 SWOT ANALYSIS OF ROCHE DIAGNOSTICS
FIG. 23 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2013)
FIG. 24 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 25 SWOT ANALYSIS OF GLAXOSMITHKLINE PLC
FIG. 26 MERCK & CO. REVENUE BY GEOGRAPHY (2013)
FIG. 27 MERCK & CO. REVENUE BY BUSINESS UNITS (2013)
FIG. 28 SWOT ANALYSIS OF MERCK & COMPANY
FIG. 29 NOVARTIS AG REVENUE BY GEOGRAPHY (2013)
FIG. 30 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 31 SWOT ANALYSIS OF NOVARTIS AG
FIG. 32 PFIZER REVENUE BY GEOGRAPHY (2013)
FIG. 33 PFIZER REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 34 SWOT ANALYSIS OF PFIZER
FIG. 35 SANOFI REVENUE BY GEOGRAPHIES (2013)
FIG. 36 SANOFI REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 37 SWOT ANALYSIS OF SANOFI
FIG. 38 ELI LILLY AND COMPANY REVENUE BY GEOGRAPHIES (2013)
FIG. 39 ELI LILLY AND COMPANY REVENUE BY BUSINESS SEGMENTS (2013)
FIG. 40 SWOT ANALYSIS OF ELI LILLY AND COMAPANY
FIG. 41 CELGENE CORPORATION REVENUE BY GEOGRAPHIES (2013)
FIG. 42 CELEGENE CORPORATION REVENUE BY PRODUCT SALES (2013)
FIG. 43 SWOT ANALYSIS OF CELGENE CORPORATION

Recent progress in targeted and biological/immunotherapies has widened the scale of therapeutic targets for the treatment of cancer by identifying tumor cell specific genes. Immunotherapies/ biologics are emerging as potent therapies to find the permanent cure from the various types of cancer. Amongst various biologics, cancer drugs market that relies on monoclonal antibodies (mAbs) have gained significant attention from pharmaceutical companies owing to high efficacy. Adjuvant application of monoclonal antibodies (mAbs) with chemotherapy has provided competitive edge for pharmaceutical companies. Therefore, development of new biological therapies for treating cancer or widening the applications of existing immunotherapeutics to cover various cancer types offers tremendous growth opportunities for manufacturers in cancer drugs market. 

Additionally, personalized medicines could also be the promising approach to find the suitable treatment solution for cancer, based on individual’s genetic makeup and their tumour biology. This approach in oncology drugs market is vital in the manufacturing of oncology drugs and could be well executed by using targeted treatments and pharmacogenomics principles that produces significant results for the cure of cancer. Despite of the excitement that personalized medicines has created, very little is known about genetic changes that occur in a malignant cell. Therefore, it is complex to develop the personalized cancer medicine. Further research in oncology drugs market especially personalized medicines approach could be highly fruitful to find the effective treatment solutions to various cancer types.

Patent expiration for the key cancer drugs has significantly increased the scope of economic biosimilar across developing regions, where the prevalence of cancer is at peak. Moreover, the migration of pharmaceutical companies in pharmerging economies such as China, India, and Brazil owing to presence of low cost labor, and less stringent government regulations has reduced the cost of cancer drugs. 

 

SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$4515
$5325
$7350
$10680
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User
$4515
Group User
$5325
Site User
$7350
Global User
$10680
buy now

Discount will be applied in cart.
First time buyer ?
Check offers and discount
on this report
GET DISCOUNT
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Micromanipulator is a device, which is used to perform intricate procedures or manipulate minute specimens using a microscope. These devices are generally used along with a microscope equipped with an input joystick, a mechanism to reduce the area of movement. They cater to a wide variety of applications ranging from cell micromanipulation to industrial micromanipulation, embracing semiconductors and electronic industries, among others.
    Nov 2015 | Price: $3516(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests.
    Sep 2014 | Price: $2625(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market.
    Sep 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Rise in incidence of diabetes across the globe has elevated the need of innovative diabetic management devices that has increased adoption of continuous glucose monitoring (CGM) devices. The existing glucose monitoring devices have few gaps which are bridged by the innovative CGM. With continuous glucose monitoring, significant improvement has been observed in stabilizing elevated A1C levels which in turn reduces risk of developing long term diabetic complications. Other driving factors for CGM market are technological innovation in the form of artificial pancreas, increasing awareness among developed, developing and under developed economies, and rise in incidences of diabetic cases.
    Dec 2013 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    5-Hydroxytryptophan (5-HTP), a natural amino acid, is a chemical precursor of biosynthetic neurotransmitters Serotonin and Melatonin. It is used as a dietary supplement, sleep aid, and appetite suppressant and is also marketed for the indication of major depression. In United Kingdom, United States, Australia and Canada, 5-HTP is sold as an over the counter (OTC) product. Serotonin, also called as 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter and it regulates the mood, sleep and appetite. Melatonin is a hormone and its effects are produced through the activation of melatonin receptors. Secretion of melatonin reduces with age and leads to insomnia. In North America Melatonin is sold as an OTC product and not regulated by FDA, whereas, in Europe and Asia-Pacific it is a prescription drug.
    Jul 2016 | View Details >>
  • ...
    Gas chromatography (GC) is a type of chromatography used for analyzing and separating compounds that can vaporize without decomposition. It is used to test purity of a substance and separating different components in a mixture.
    Jul 2016 | View Details >>
  • ...
    Prepacked columns are ready-to-use columns for chromatography testing, which are standardized high-performance bioprocessing columns prepacked with a range of bioprocess media. It is used in several chromatographic applications, such as separation of proteins, DNA, plasmids, endotoxins, vaccines and viruses.
    Jul 2016 | View Details >>
  • ...
    Multiple sclerosis (MS) is an inflammatory disease of nervous system, which is also referred as disseminated sclerosis. Multiple sclerosis is progressed with disruption spinal cord and brain nerve cells, which results in loss of ability of the parts of the nervous system to communicate including various other mental, physical and psychiatric problems. Primary progressive multiple sclerosis (PPMS) is the type of multiple sclerosis in which neurological functions are steadily deteriorated with minimal distinct relapses (exacerbations and attacks) or the fixed period remissions.
    Jul 2016 | View Details >>